Argenica Therapeutics Ltd · ASX:AGN

Argenica Therapeutics — 49th Annual Fetal and Neonatal Physiological Society (FNPS) Meeting 2023

13 slides from Argenica Therapeutics's conference presentation, Sep 4, 2023

1. Slide 1: Argenica to present ARG-007 data at Fetal and Neonatal Scientific Conference

   ASX ANNOUNCEMENT ARGENICA TO PRESENT ARG-007 DATA AT FETAL AND NEONATAL SCIENTIFIC CONFERENCE Perth, Australia; 4 September 2023 - Argenica Therapeutics Limited (ASX: AGN) (“Argenica” or the “Company”), a biotechnology company developing novel therapeutics to reduce brain tissue death after stroke a

2. Slide 2: ARG-007: a promising neuroprotective peptide for hypoxic ischaemic encephalopathy

   ARG-007: a promising neuroprotective peptide for hypoxic ischaemic encephalopathy Adam B. Edwards, Vincent W. Clark, Aline Domingos, Rachel Glossop, Neville W. Knuckey, Bruno P. Meloni

3. Slide 3: Disclaimer

   Disclaimer Argenica Therapeutics Ltd is the commercial entity leading the clinical development of ARG-007 as a neurotherapeutic  Appointments  Shareholder of Argenica Therapeutics Ltd  Neonatal Scientific and Regulatory Advisor of Argenica Therapeutics Ltd

4. Slide 4: Presentation overview

   Presentation overview  The unmet need in HIE ARG-007 as a neurotherapeutic Modified Rice-Vannucci rat model of HIE ARG-007 efficacy PND7 and PND10 rats Future directions

5. Slide 5: The unmet need in HIE

   The unmet need in HIE Sentinel event ≥ 35 weeks gestation Developed LMICs 3 in 1,000 26 in 1,000 Therapeutic hypothermia Neonatal neurocritical care post-HELIX 33.5°C for 72 hours No advisable neuroprotective strategy 46% of infants receive no benefit ARG-007 neurotherapeutic potential ARG-007 neuro

6. Slide 6: ARG-007 as a neurotherapeutic (Frontiers in Neurology, 2020)

   ARG-007 as a neurotherapeutic Frontiers in Neurology, 2020, Meloni et al

7. Slide 7: ARG-007 as a neurotherapeutic (Neurotherapeutics, 2020)

   ARG-007 as a neurotherapeutic Neurotherapeutics, 2020, Meloni et al

8. Slide 8: Modified Rice-Vannucci model

   Modified Rice-Vannucci model + J Neuro Methods 2017, Edwards et al

9. Slide 9: ARG-007 efficacy in the PND7 rat

   ARG-007 efficacy in the PND7 rat ARG-007 efficacy as a standalone therapy ARG-007 efficacy after P = .02 hypothermia P = .01 200 ✱✱✱ GM/IVH volume mm3 ✱✱✱ 44% reduction 40 51% reduciton 150 Infarct mm3 20 100 0 Saline 300 1000 50 0 Saline Saline 100 300 ASX Announcement 3 November 2021

10. Slide 10: ARG-007 efficacy in the PND7 rat (unpublished observation)

    ARG-007 efficacy in the PND7 rat ASX Announcement 3 November 2021 Unpublished observation

11. Slide 11: ARG-007 efficacy in the PND10 rat

    ARG-007 efficacy in the PND10 rat Neuropathological correlates: Infarct 4 weeks post-HI  Neocortical infarct Infarct 48 h post-HI ✱  Striatal infarct ✱  Subcortical infarct ✱✱ ✱✱  Foci haemorrhage ✱ ✱ 400 200 Infarct volume mm3 300 Infarct volume mm3 150 100 200 50 100 0 0 Saline 100 300 600 Sal

12. Slide 12: Future planned studies

    Future planned studies ARG-007 neuroprotection in ARG-007 neuroprotection in term asphyxia with recovery preterm asphyxia ± LPS and 25 day behavioural challenge assessments

13. Slide 13: Acknowledgements

    Acknowledgements  Research Funding Prof Bruno Meloni Argenica Therapeutics Ltd Prof Neville Knuckey Stan Perron Charitable Foundation Prof Jane Pillow Telethon Perth Children’s Hospital Research Fund A/Prof Kasper Kyng Channel 7 Telethon Trust Dr Tim Rosenow Charlies Foundation for Research Dr Kir

Argenica Therapeutics — 49th Annual Fetal and Neonatal Physiological Society (FNPS) Meeting 2023 on 6ix